Announcements
Supplementary statements on news article
Date of occurrence of the event: Jun 23, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: Not …
Announcement of resolution items from 2020 Annual General Meeting
Date of the shareholders’ meeting: Jun 22, 2020 Important resolutions I. Profit distribution/deficit compensation: Resolution on acknowledgment of 2019 Deficit Compensation Important resolutions II. Amendments of the company charter: None …
Announcement of 2020 annual general meeting passes removal of the noncompete clause for directors
Date of the shareholders’ meeting resolution: Jun 22, 2020 Name and title of the managerial officer with permission to engage in competitive conduct: Director: Frank Chen (Sheng Cheng Investment Co., …
OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA
OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA Date of occurrence of the event: Jun 10, 2020 Company name: OBI Pharma …
OBI has filed application of Phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA
Date of occurrence of the event: May 29, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not …
OBI has signed a non-binding MOU to form a strategic partnership to develop novel bispecific antibody cancer treatments
Date of occurrence of the event:26 May 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No applicable …
Supplementary statement for 2020 Shareholders’ Meeting (Change in location and new items)
Date of the board of directors resolution:May 08, 2020 Date for convening the shareholders’ meeting:Jun 22, 2020 Location for convening the shareholders’ meeting:Courtyard Taipei, 7F Supernova Ballroom (7F, No.359, Sec. …
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by Ministry of Food and Drug Safety of South Korea to proceed Phase III human clinical study
Date of occurrence of the event: Apr 10, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No …
Due to the tense situation of Novel Coronavirus Disease (COVID-19), company decided to pause the recruitment of Global Phase III clinical study for 3 months and will restart recruitment when epidemic gets controlled.
Date of occurrence of the event: Apr 06, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: No …
Updates on company’s negotiable securities for investors’ information
1.Date of occurrence of the event: Mar 23, 2020 2.Cause of occurrence: Notified by Taipei Exchange (TPEx) to release information 3.Financial and business information: (1 ) Latest 1 month SUBJECT …